Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
J Clin Lab Anal. 2022 Nov;36(11):e24740. doi: 10.1002/jcla.24740. Epub 2022 Oct 25.
Non-small-cell lung cancer (NSCLC) still occupied the leading reason of cancer death due to lack of availability of early detection. This study aimed to identify the effective biomarkers for the early-stage NSCLC diagnostics based on plasma snoRNAs.
The differential snoRNAs between lung cancer patients and healthy donors were analyzed using the SNORic and TCGA databases. SNORD42B and SNORD111 were screened out and further verified in 48 FFPE NSCLC and adjacent normal tissues, as well as in plasma from 165 NSCLC patients and 118 health donors using qRT-PCR. Next, their diagnostic efficiency, as well as combined with carcinoembryonic antigen (CEA), was obtained by the analysis of receiver operating characteristic (ROC).
We first screened out 47 top differential snoRNAs, among which the top 10 upregulated snoRNAs in LUAD were U44, U75, U78, U77, SNORD72, SNORD13, SNORD12B, SCARNA5, U80, SNORD41, and in LUSC were U44, U75, U78, SNORD41, SNORD111, SNORA56, U17a, SNORD35A, SNORD32A, SNORA71D. SNORD42B and SNORD111 was significantly increased not only in tumor tissues but also in plasma from NSCLC and early-stage NSCLC patients. They were capable to act as promising biomarkers for NSCLC and early-stage NSCLC diagnosis. Moreover, CEA diagnostic efficiency for early-stage NSCLC was significantly improved when combined with these two plasma snoRNAs.
SNORD42B and SNORD111 could act as the potential and non-invasive diagnostic biomarkers for NSCLC and early-stage NSCLC.
由于缺乏早期检测手段，非小细胞肺癌（NSCLC）仍然是癌症死亡的主要原因。本研究旨在基于血浆 snoRNA 鉴定用于早期 NSCLC 诊断的有效生物标志物。
利用 SNORic 和 TCGA 数据库分析肺癌患者和健康供体之间差异表达的 snoRNA。筛选出 SNORD42B 和 SNORD111，并在 48 例 FFPE NSCLC 及相邻正常组织以及 165 例 NSCLC 患者和 118 例健康供体的血浆中通过 qRT-PCR 进一步验证。接下来，通过分析受试者工作特征（ROC）曲线获得其诊断效率，以及与癌胚抗原（CEA）联合的诊断效率。
我们首先筛选出 47 个差异表达 snoRNA，其中 LUAD 中上调最明显的 10 个 snoRNA 是 U44、U75、U78、U77、SNORD72、SNORD13、SNORD12B、SCARNA5、U80、SNORD41，LUSC 中上调最明显的是 U44、U75、U78、SNORD41、SNORD111、SNORA56、U17a、SNORD35A、SNORD32A、SNORA71D。SNORD42B 和 SNORD111 不仅在肿瘤组织中，而且在 NSCLC 和早期 NSCLC 患者的血浆中均显著升高。它们可以作为 NSCLC 和早期 NSCLC 诊断的有前途的生物标志物。此外，当与这两种血浆 snoRNA 联合使用时，CEA 对早期 NSCLC 的诊断效率显著提高。
SNORD42B 和 SNORD111 可以作为 NSCLC 和早期 NSCLC 的潜在非侵入性诊断生物标志物。
